News Home

Eiger Biopharmaceuticals Inc (EIGR) Stock: Do Analysts Think You Should Hold?

Thursday, October 28, 2021 09:57 AM | InvestorsObserver Analysts
Eiger Biopharmaceuticals Inc (EIGR) Stock: Do Analysts Think You Should Hold?

Analysts who follow Eiger Biopharmaceuticals Inc (EIGR) on average expect it to increase 389.13% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy. That average rating earns the stock an Analyst Ranking of 75, which means it ranks higher than 75 of stocks, based on data compiled by InvestorsObserver.

Overall Score - 5
Wall Street analysts are rating EIGR a Strong Buy today. Find out what this means to you and get the rest of the rankings on EIGR!

Why are Analyst Ratings Important?

Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve. InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.

What's Happening With Eiger Biopharmaceuticals Inc Stock Today?

Eiger Biopharmaceuticals Inc (EIGR) stock is trading at $6.44 as of 9:43 AM on Thursday, Oct 28, a rise of $0.58, or 9.9% from the previous closing price of $5.86. The stock has traded between $5.91 and $6.45 so far today. Volume today is low. So far 115 shares have traded compared to average volume of 184,537 shares. Click Here to get the full Stock Report for Eiger Biopharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App